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Implementation of an in-house designed skeletal dysplasia gene 
panel as a first screening step to diagnose unsolved osteogenesis 
imperfecta (–like) patients
The pace of disease-related gene discovery has
accelerated phenomenally in recent years due to
advances of next generation sequencing (NGS)
technologies, such as whole exome sequencing
(WES). In the field of skeletal dysplasias, particularly
for osteogenesis imperfecta (OI), NGS added a
remarkable number of disease loci, thereby
expanding the brittle bone disease to a
predominantly collagen-related disorder. However,
for a small subset of OI patients the genetic cause
remains elusive. We designed a skeletal dysplasia
gene panel and evaluated the detection rate in a
cohort of unsolved OI (-like) patients.
Twenty-one OI-like patients, in who no type I
collagen defect was detected, were selected
based on clinical severity (most patients had
multiple fractures) and positive familial anamnesis
(patients with a consanguineous background were
prioritized during the selection procedure). WES
sample prep was performed using the Agilent
SureSelect XT target enrichment system.
Figure 1: Whole exome sequencing, facts and figures.1,2
Guillemyn B.1, Syx D.1, Rosseel T.1, Kayserili H.2, Cueto-González AM.3, 
Van Maldergem L4, Menten B1, De Paepe A.1, Coucke P.1, 
Malfait F.1, Symoens S.1
Targeted sequencing
WES is perhaps the most widely 
used targeted sequencing 
method
Exome vs 
genome
The exome, the 
protein-coding 
region of the 
human genome, 
accounts for less 
than 2% of the 
genome but 
contains ~85% of 
known disease-
related variants
Success 
rate
In clinical 
setting, 
reported 
detection 
rates for 
deleterious 
mutations 
range from 
25 to 50% 
WES libraries were sequenced on Illumina platforms, data were
analysed by SeqPlorer (an in-house developed pipeline, which
integrates population database information/quality
scores/coverage data and in silico prediction algorithms).
The generated data was mapped against a newly designed
skeletal dysplasia gene panel, including 566 genes. This gene
panel includes known loci for heritable skeletal disorders, but
also candidate genes for bone fragility are included (which are
the result of GWAS and animal studies linking aberrant BMD
scores to candidate genes for osteoporosis).3,4,5,6,7
Figure 2: Methods used in this study.
Clinical 
phenotype
LEPRE1 – case (male, 2y)
Six fractures in first 2 years, short stature, 
triangular face, brachiocephaly, flat 
occiput, psychomotor retardation
ALPL – case (female, 1y)
No fractures, short stature, 
blue sclerae, dimples, bowed 
humeri
CTSK – case (female, 16y)
Multiple fractures, osteopetrosis, mild short 
stature, long palpebral fissure, pinched nose 
with long columella, blue sclerae, 
dentinogenesis imperfecta
Protein change
Clinical diagnosis
Variant classification 
DEOGEN2 8,9
p.[(Leu149Arg)];[(Leu149Arg)] p.[(His482Asn)];[(His482Asn)] p.[(Arg241*)];[(Arg241*)]
autosomal recessive (AR) OI AR hypophosphatasia AR osteopetrosis
DEOGEN2 is not applicable 
for nonsense variants
CLASS 3 CLASS 3 CLASS 5 
Figure 3: Overview of the 3 solved cases.
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Figure 4: Average
skeletal dysplasia gene
panel coverage of the
21 exomes included in
this study. An exome is
considered as ‘well
sequenced’ if more
than 95% of the bases is
20x covered. Error bars,
SD.
Prolyl-3-hydroxylase-1 (P3H1) is required 
for proper collagen biosynthesis, 
folding, and assembly
Cathepsin K is a cysteine protease which 
digests bone matrix proteins during bone 
resorption.
Liver / bone / kidney alkaline 
phosphatases are membrane-
bound glycoproteins, playing a 
role in bone mineralization.
Protein function
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Searching for 
the needle in 
the haystack
An average of 
41636 variants 
were generated 
using the 
GRCh38/hg38 
build across the 
21 exome 
samples included 
in this study
Applications
Exome sequencing can 
efficiently identify coding 
variants across a wide range of 
applications, including 
population genetics, genetic 
disease, and cancer studies
Conclusions and future perspectives
Our findings show that the implementation of this skeletal dysplasia gene panel is a powerful first
screening step in molecularly diagnosing OI(-like) patients, especially for those patients whom are
difficult to diagnose due to phenotypically overlapping clinical symptoms.
With regards to the 18 unsolved exome cases: with the use of SeqPlorer, we were able to generate
a shortlist of 71 variants in total, of which further prioritization, confirmational sanger sequencing,
segregational analysis and functional studies will have to aid in the elucidation of these cases.
Besides the used seqplorer pipeline, we are currently testing tools in order to pick up copy number
variations from the same exome datasets (such as cn.MOPS, CoNIFER and ExomeDepth).
